

-26-

WHAT IS CLAIMED IS

1. A formulation for targeting an infectious agent which acquires a HLA-DR host membrane protein during its life cycle or a HLA-DR expressing host cell or both, said
5 formulation comprising a ligand capable of binding to said host membrane protein, said ligand being coupled to a lipid-comprising vesicle.
2. A formulation according to claim 1 wherein lipid-comprising vesicle is a liposome.
10
3. A formulation according to claim 2 wherein said liposome comprises a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio ranging between 10:1 and 1:1, wherein the acyl chains are either saturated or unsaturated and have between 14 and 18 carbon atoms in length.
15
4. A formulation according to claim 3, wherein said lipid component comprises a polyethyleneglycol derivative of diacylphosphatidylethanolamine.
5. A formulation according to claim 4, wherein the polyethyleneglycol has a
20 molecular weight comprises between about 500 and 5000 daltons.
6. A formulation according to claim 3, wherein the molar ratio is 10:3.
7. A formulation according to claim 4 or 5, wherein said lipid component
25 comprises a mixture of diacylphosphatidylcholine:diacylphosphatidylglycerol:diacylphosphatidylethanol-amine-polyethyleneglycol in a molar ratio of 10:3:0.1-3.
8. A formulation according to claim 2, 3 or 6, wherein said lipid component comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol in a
30 molar ratio of 10:3 or distearoylphosphatidylcholine:distearoylphosphatidylglycerol in a molar ratio of 10:3.
9. A formulation according to claim 2, 3, 4, 5 or 7, wherein said lipid component comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol:
35 dipalmitoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.33 or dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol:distearoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.83.

ART 34 AMDT

DATE	TIME	LOCATION	REMARKS
1900	10:00	1000	1000
1901	10:00	1000	1000
1902	10:00	1000	1000
1903	10:00	1000	1000
1904	10:00	1000	1000
1905	10:00	1000	1000
1906	10:00	1000	1000
1907	10:00	1000	1000
1908	10:00	1000	1000
1909	10:00	1000	1000
1910	10:00	1000	1000
1911	10:00	1000	1000
1912	10:00	1000	1000
1913	10:00	1000	1000
1914	10:00	1000	1000
1915	10:00	1000	1000
1916	10:00	1000	1000
1917	10:00	1000	1000
1918	10:00	1000	1000
1919	10:00	1000	1000
1920	10:00	1000	1000
1921	10:00	1000	1000
1922	10:00	1000	1000
1923	10:00	1000	1000
1924	10:00	1000	1000
1925	10:00	1000	1000
1926	10:00	1000	1000
1927	10:00	1000	1000
1928	10:00	1000	1000
1929	10:00	1000	1000
1930	10:00	1000	1000
1931	10:00	1000	1000
1932	10:00	1000	1000
1933	10:00	1000	1000
1934	10:00	1000	1000
1935	10:00	1000	1000
1936	10:00	1000	1000
1937	10:00	1000	1000
1938	10:00	1000	1000
1939	10:00	1000	1000
1940	10:00	1000	1000
1941	10:00	1000	1000
1942	10:00	1000	1000
1943	10:00	1000	1000
1944	10:00	1000	1000
1945	10:00	1000	1000
1946	10:00	1000	1000
1947	10:00	1000	1000
1948	10:00	1000	1000
1949	10:00	1000	1000
1950	10:00	1000	1000
1951	10:00	1000	1000
1952	10:00	1000	1000
1953	10:00	1000	1000
1954	10:00	1000	1000
1955	10:00	1000	1000
1956	10:00	1000	1000
1957	10:00	1000	1000
1958	10:00	1000	1000
1959	10:00	1000	1000
1960	10:00	1000	1000
1961	10:00	1000	1000
1962	10:00	1000	1000
1963	10:00	1000	1000
1964	10:00	1000	1000
1965	10:00	1000	1000
1966	10:00	1000	1000
1967	10:00	1000	1000
1968	10:00	1000	1000
1969	10:00	1000	1000
1970	10:00	1000	1000
1971	10:00	1000	1000
1972	10:00	1000	1000
1973	10:00	1000	1000
1974	10:00	1000	1000
1975	10:00	1000	1000
1976	10:00	1000	1000
1977	10:00	1000	1000
1978	10:00	1000	1000
1979	10:00	1000	1000
1980	10:00	1000	1000
1981	10:00	1000	1000
1982	10:00	1000	1000
1983	10:00	1000	1000
1984			

- ART 34 AMDT

-28-

21. The use of a formulation according to any one of claims 1 to 20 for treating or preventing a disease caused by said infectious agent.

5 22. The use of a ligand to a host membrane protein which is acquired by an infectious agent during its life cycle in the making of a formulation for targeting said infectious agent and its host cell, said ligand being coupled to a lipid-comprising vesicle and said protein does not consist of CD4 or of a HLA class 1 protein.

10 23. The use as defined in claim 22, wherein said formulation is defined in any one of claims 1 to 20.

00922374.4(03-05-2000) - CA00/00469(03-05-2000)

ART 34 AMDT